As patents for key blockbuster drugs begin to expire and plant use begins to wane, experts are looking to Europe for a boom in contract manufacturing. According to consultancy firm Frost & Sullivan, CMO revenue on the Continent should double over the next 6 years, with pharma outsourcing expected to reach $20.75 billion, up from $10.02 billion last year. Of course, as that trend continues to grow, so can risks--like drug contamination, recalls and safety issues--which should result tighter rules and regulations, and that can put pressure on CMOs, according to the Frost & Sullivan analysts. More details can be found in Eric Palmer's story on FiercePharmaManufacturing. More